NEW YORK – Twist Bioscience and China's Berry Genomics on Monday announced a partnership on next-generation sequencing target enrichment and library preparation tools.
Under their agreement, the firms will work together to develop new research and in vitro diagnostic NGS panels for inherited diseases.
Berry Genomics will also offer Twist's NGS panels for cancer diagnosis.
Financial and other details of the deal were not disclosed.
South San Francisco, California-based Twist offers NGS-based genotyping assays using its synthetic oligonucleotides to capture target sequences. NGS products became the company's top revenue generator in the company's first quarter of fiscal year 2021, which ended Dec. 31, 2020.
Last year, Berry Genomics partnered with cancer genomics firm Personalis to facilitate the latter company's expansion into China. Berry also has a partnership on clinical sequencing with Illumina.